Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.
- Nonmetastatic castration-resistant prostate cancer
- Overall survival
- Subsequent therapy
- Time to cytotoxic chemotherapy
ASJC Scopus subject areas